Today: 29 April 2026
Browse Category

Biotechnology 21 October 2025 - 3 November 2025

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics shares jumped about 14% pre-market Nov. 3, 2025, trading near $2.27, down roughly 85% from its $12.50 IPO in 2022. Interim Phase 2b data for lead drug ACR-368 showed a 35% response rate in advanced endometrial cancer. The FDA granted Fast Track status to ACR-368 and Breakthrough Device designation to its companion diagnostic. Acrivon employs around 78 people in Watertown, MA.
3 November 2025
··
Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Caribou Biosciences reported its off-the-shelf CAR-T therapy vispa-cel achieved a 64% complete remission rate in lymphoma, with 51% of patients cancer-free after one year. In multiple myeloma, CB-011 showed a 92% overall response rate. Shares of Caribou more than doubled after the Nov. 3 announcement. No graft-vs-host disease was observed, though one fatal toxicity occurred.
3 November 2025
··
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

The FDA will announce a new fast-track approval process for personalized gene-editing therapies in early November, sending CRISPR Therapeutics shares up 8% and Editas up 12%. CRSP reported over 90% mRNA correction in preclinical CTX460 data and will present Phase 1 CTX310 results at the AHA conference Nov. 8. Intellia paused a TTR amyloidosis trial after a liver injury, causing its stock to fall 46%.
2 November 2025
······
Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Cabaletta Bio shares surged up to 46% on Oct. 31, closing at $3.61 after strong CAR-T therapy data, with trading volume hitting 35.7 million shares. Phase 1/2 results showed major improvements in myositis and systemic sclerosis, and durable lupus nephritis remissions. The company remains pre-revenue, holding $194.7 million cash as of June 30. Wall Street analysts mostly rate CABA a “Buy,” with targets averaging $13–15.
31 October 2025
··
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health shares soared nearly 30% to around $94 on Oct. 30, 2025, after Q3 revenue jumped 39% to $265.2 million, beating estimates. The company raised its 2025 revenue outlook to $965–970 million. New partnerships are expanding access to its Shield colorectal cancer test nationwide. Guardant360 received additional FDA approvals and a formal review submission.
30 October 2025
··
Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

Harvard Bioscience shares fell to $0.40 in October 2025, down 84% year-over-year, after hitting a 52-week low of $0.28. Nasdaq granted a 180-day extension to regain $1 compliance, and the company is considering a reverse split. Q2 revenue dropped 12% to $20.5 million, but cash flow improved. Debt refinancing is required by December 2025, and John Duke became CEO in July after Jim Green’s retirement.
30 October 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk launched an $8.5 billion unsolicited bid for obesity drugmaker Metsera, topping Pfizer’s $7.3 billion agreed deal. Novo’s offer values Metsera at $56.50 per share in cash plus up to $21.25 in milestone payments. Metsera shares jumped 18% premarket, while Novo’s stock fell 3%. Pfizer called Novo’s bid “reckless” and warned it could harm competition.
30 October 2025
····
Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Therapeutics shares plunged nearly 45% on Oct. 27 after the company halted two Phase 3 trials of its CRISPR therapy due to a patient suffering severe liver toxicity. The stock dropped from the mid-$20s to the low-teens, with NTLA trading around $14–15 as of midday Oct. 28. Several analysts downgraded the stock and cut price targets following the safety incident.
28 October 2025
···
Co-Diagnostics (CODX) Stock Skyrockets 200% on Saudi JV – Is This Just the Beginning?

Co-Diagnostics (CODX) Stock Skyrockets 200% on Saudi JV – Is This Just the Beginning?

Co-Diagnostics shares jumped over 200% to close at $1.07 on October 27 after announcing a joint venture with Arabian Eagle Manufacturing to distribute PCR tests across the Middle East and North Africa. Trading volume topped 100 million shares amid a surge in retail investor activity. The company recently reported Q2 revenue of $200,000, down sharply from the prior year. Analyst price targets ranged from $1.00 to $3.00.
27 October 2025
··
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics shares plunged nearly 45% Monday after the company halted two Phase 3 trials of its CRISPR therapy NTLA-2001 due to a severe liver injury in a patient. The stock dropped from about $19 to the low teens, with CRISPR Therapeutics also falling 10%. Intellia paused dosing and enrollment following the Grade 4 liver event and is consulting regulators on next steps.
27 October 2025
···
CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics traded near $67 on Oct. 27, down 3% after safety concerns hit gene-editing stocks. Shares remain up nearly 100% in 2025, fueled by a major preclinical breakthrough and global rollout of its Casgevy therapy. Rival Intellia plunged 45% after a trial pause, dragging CRSP down 10% in sympathy. Analysts remain bullish, with targets up to $93 despite sector volatility.
27 October 2025
··
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Novartis will acquire Avidity Biosciences for $72 per share in cash, a deal valuing Avidity at $12 billion and marking a 46% premium over its last close. The transaction, announced Oct. 26, 2025, is expected to close in the first half of 2026. Before closing, Avidity will spin off its early-stage cardiology programs into a new company, with shareholders receiving both cash and SpinCo shares.
27 October 2025
·····
Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

Recursion Pharmaceuticals closed at $6.04 on Oct. 24, 2025, after volatile trading and a 44% monthly surge. Q2 revenue rose 33% to $19.2 million, but net loss reached $171.9 million as R&D spending climbed. The company completed a $630 million merger with Exscientia and reported $534 million cash on hand. Key drug candidates advanced in clinical trials, with several late-stage readouts expected by year-end.
26 October 2025
···
NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis announced FDA 510(k) clearance for its PENFS device to treat adult functional dyspepsia on Oct. 24, marking the first approved therapy for this condition. NRXS shares rose to $3.82 on Oct. 23 and traded higher pre-market after the news. The company recently raised $5 million and expanded insurance coverage to 53 million lives. Q2 revenue grew 46% year-over-year; analyst sentiment remains mixed.
24 October 2025
··
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

RVPH shares closed at $0.57 on Oct 24 after a volatile month, swinging between $0.26 and $0.84. The stock surged 28% on Oct 23 following recent Phase 3 trial results for brilaroxazine and news of an upcoming FDA meeting. Reviva raised about $19 million this year to fund its CNS pipeline. Analyst targets average $6.25, implying a potential 1,000% upside.
24 October 2025
···
Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science shares surged over 300% in early trading Oct. 24 after announcing an expanded partnership with Anemocyte to develop off-the-shelf lentiviral vector plasmid DNA for cell therapies. The company’s lead candidate Temferon showed a 29% two-year survival rate in glioblastoma patients, more than double standard care. Net loss narrowed to €3.83M in H1 2025. Analyst targets average $22.73, far above current prices.
24 October 2025
··
Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx’s ozekibart cut risk of progression or death by 52% in Phase 2 chondrosarcoma trial, doubling median progression-free survival to 5.52 months versus placebo. Shares of INBX jumped about 70% intraday and closed at $28.36 on Oct. 23, then surged another 75–80% after hours. Management plans a BLA filing in Q2 2026. Ozekibart also showed high response rates in colorectal and Ewing sarcoma cohorts.
24 October 2025
··
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics shares rose about 17% to $30 after the FDA granted RMAT and Orphan Drug designations to its lead gene-editing programs, BEAM-101 and BEAM-302. Early trial data showed BEAM-302 raised protective AAT levels and BEAM-101 produced durable increases in fetal hemoglobin. Wall Street’s average 12-month price target is $45–46, implying roughly 70–80% upside.
21 October 2025
··
1 … 11 12 13 14 15 16

Stock Market Today

  • METAWATER Analysts Boost Earnings Forecasts After Fiscal Year Results
    April 28, 2026, 10:25 PM EDT. METAWATER Co., Ltd. (TSE:9551) reported full-year results showing revenues of JP¥210 billion, 3.4% above forecasts, while earnings per share (EPS) matched analyst expectations. Following these results, five analysts raised their 2027 forecasts to JP¥220.7 billion in revenue and JP¥220 EPS, indicating a 5.2% and 5.0% increase respectively. The consensus price target jumped 17% to JP¥3,100, reflecting improved earnings outlook. Despite recent share declines of 7.5% post-report, analysts remain cautiously optimistic, noting that forecast revenue growth aligns closely with industry averages but slows from historic rates. Analyst price targets range from JP¥2,000 to JP¥3,800, suggesting moderate divergence in sentiment. Overall, the earnings upgrade underscores increased confidence in METAWATER's future profitability.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop